MRT-6160 is under clinical development by Monte Rosa Therapeutics and currently in Phase I for Rheumatoid Arthritis. According to GlobalData, Phase I drugs for Rheumatoid Arthritis have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MRT-6160’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MRT-6160 overview

MRT-6160 is under development for the treatment of axial spondyloarthritis, rheumatoid arthritis, multiple sclerosis, Myasthenia Gravis, psoriasis, cutaneous lupus erythematosus and ulcerative colitis. They are molecule glue degraders (MGD) and are being developed based on Quantitative and Engineered Elimination of Neo substrates (QuEEN) platform. They act by targeting vav guanine nucleotide exchange factor 1 (VAV1). It is administered through oral route as tablet.
It was under development for the treatment of hematological tumors such as T and B-cell lymphomas.

Monte Rosa Therapeutics overview

Monte Rosa Therapeutics is a biotechnology company developing small molecules to degrade disease-related proteins. The company is headquartered in Boston, Massachusetts, the US.

For a complete picture of MRT-6160’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.